RxPONDER Data Published!

Read the press release to learn more about how the newly published RxPONDER data helps inform treatment for node positive patients.

Redesigned Clinically Low-Risk Report

Oncotype DX Genomic Prostate Score Assay

Introducing the newly re-designed Oncotype DX GPS assay report for clinically low-risk prostate cancer patients.

20-Year Outcomes: Adverse Pathology

Oncotype DX Genomic Prostate Score Assay

New follow-up data suggests adverse pathology as a predictor of prostate cancer specific mortality and metastasis for clinically low-risk prostate cancer patients for up to 20 years after diagnosis.

2021 SABCS® Meeting

December 7-10, 2021

Visit us at 2021 SABCS® to learn more about how the Oncotype test portfolio can help guide treatment decisions for your breast cancer patients.

AONN Webinar Supported by Exact Sciences

December 16, 2021, 12-1pm ET

Join us for a live webinar, “Empowering the Patient Voice: Genomic Testing and Cancer Care Decisions." A panel of experts will discuss the critical role of nurse navigators in educating cancer patients about genomic testing and how to interpret the test results.
Making cancer care smarter.®